CE / CME
This series of on-demand webcasts brings you experts’ perspectives on the top abstracts from the 2023 American Society of Hematology Annual Meeting, segmented by topic—leukemias, lymphomas, multiple myeloma, myeloproliferative neoplasms, and nonmalignant hematologic malignancies. Learn how these new data will affect your clinical practice.
Physician Assistants/Physician Associates: 4.75 AAPA Category 1 CME credits
Nurses: 4.75 Nursing contact hours
Physicians: maximum of 4.75 AMA PRA Category 1 Credits™
Pharmacists: 4.75 contact hours (0.475 CEUs)
Released: February 01, 2024
Expiration: January 31, 2025
Share
Catherine M. Broome, MD
Professor of Medicine
Division of Hematology/Oncology
MedStar Georgetown University Hospital
Washington, DC
Ian Flinn, MD, PhD
Chief Scientific Officer
OneOncology
Nashville, Tennessee
Sagar Lonial, MD, FACP
Chair and Professor
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia
Raajit K. Rampal, MD, PhD
Associate Member
Director, MPN and Rare Hematologic Malignancies Program
Director, Center for Hematologic Malignancies
Memorial Sloan Kettering Cancer Center
New York, New York
Eunice S. Wang, MD
Chief, Leukemia and Benign Hematology Service
Professor of Oncology
Roswell Park Comprehensive Cancer Center
Buffalo, New York
Provided by Clinical Care Options, LLC
Supported by educational grants from AbbVie Inc., AstraZeneca, Daiichi Sankyo, Inc., Merck Sharp & Dohme LLC, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc, and Seagen Inc.
AbbVie Inc.
AstraZeneca
Daiichi Sankyo, Inc.
Merck Sharp & Dohme, LLC
Novartis Pharmaceuticals Corporation
Regeneron Pharmaceuticals, Inc
Seagen Inc.
This program is intended for healthcare professionals, nurses, pharmacists, and physician associates who care for patients with malignant or nonmalignant hematologic disorders.
This activity aims to improve learners’ understanding of how to optimally apply recent practice-changing findings in the treatment of patients with malignant or nonmalignant hematologic disorders.
Upon completion of this activity, participants should be able to:
Apply recently presented data to clinical practice to expand treatment options and improve outcomes for patients with malignant or nonmalignant hematologic disorders
Evaluate new data on novel agents and therapeutic approaches for patients with malignant or nonmalignant hematologic disorders
Appraise how new trial findings might affect treatment of patients with malignant or nonmalignant hematologic disorders in the future
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Primary Author
Catherine M. Broome, MD
Professor of Medicine
Division of Hematology/Oncology
MedStar Georgetown University Hospital
Washington, DC
Catherine Broome, MD: consultant/advisor/speaker: Alexion, Argenx, Incyte, Sanofi; researcher: Alpine, Rigel, Star Therapeutics.
Ian Flinn, MD, PhD
Chief Scientific Officer
OneOncology
Nashville, Tennessee
Ian W. Flinn, MD, PhD: consultant (paid to institution): AbbVie, BeiGene, Genentech, Genmab, Hutchison MediPharma, InnoCare Pharma, Kite Pharma, Myeloid Therapeutics, Novartis, Secura Bio, Servier Pharmaceuticals, TG Therapeutics, Xencor; researcher (paid to institution): AbbVie, Acerta Pharma, Agios, ArQule, AstraZeneca, BeiGene, Biopath, Bristol Myers Squibb, CALIBR, CALGB, Celgene, City of Hope National Medical Center, Constellation Pharmaceuticals, Curis, CTI Biopharma, Epizyme, Fate Therapeutics, Forma Therapeutics, Forty Seven, Genentech, Gilead Sciences, InnoCare Pharma, IGM Biosciences, Incyte, Infinity Pharmaceuticals, Janssen, Kite Pharma, Loxo, Marker Therapeutics, Merck, Millennium Pharmaceuticals, MorphoSys, Myeloid Therapeutics, Novartis, Nurix, Pfizer, Pharmacyclics, Portola Pharmaceuticals, Rhizen Pharmaceuticals, Roche, Seattle Genetics, Step Pharma, Tessa Therapeutics, TG Therapeutics, Trillium Therapeutics, Triphase Research & Development Corp., Unum Therapeutics, Verastem, Vincerx Pharma, 2seventy bio.
Sagar Lonial, MD, FACP
Chair and Professor
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia
Sagar Lonial, MD: consultant/advisor/speaker: AbbVie, Amgen, Bristol Myers Squibb, Celgene, Genentech, GlaxoSmithKline, Janssen, Novartis, Pfizer, Regeneron, Takeda; independent contractor: TG Therapeutics.
Raajit K. Rampal, MD, PhD
Associate Member
Director, MPN and Rare Hematologic Malignancies Program
Director, Center for Hematologic Malignancies
Memorial Sloan Kettering Cancer Center
New York, New York
Raajit Rampal, MD, PhD: consultant/advisor/speaker: AbbVie, Blueprint, Bristol Myers Squibb, Cogent, CTI, Galecto, GlaxoSmithKline, Incyte, Kartos, MorphoSys, PharmaEssentia, SDP, Servier, Stemline, Zentalis.
Eunice S. Wang, MD
Chief, Leukemia and Benign Hematology Service
Professor of Oncology
Roswell Park Comprehensive Cancer Center
Buffalo, New York
Eunice S. Wang, MD: consultant/advisor/speaker: AbbVie, Astellas, Bristol-Myers Squibb, CTI Biopharma, Daiichi Sankyo, Dava Oncology, Gilead, GlaxoSmithKline, Immunogen, Janssen, Kite, Kura, Novartis, Nuprobe, Qiagen, Pfizer, Rigel, Schrodinger, Sellas, Sumitomo, Syndas.
The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.
Participation in this self-study activity should be completed in approximately 4.75 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from February 01, 2024, through January 31, 2025:
You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.
This program has been made available online.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
CCO designates this enduring material for a maximum of 4.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 4.75 contact hours.
Continuing Pharmacy Education
CCO designates this continuing education activity for 4.75 contact hour (0.475 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-24-059-H01-P
Type of Activity: Application
Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.
Physician Associate Continuing Medical Education
Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 4.75 AAPA Category 1 CME credits. Approval is valid until January 31, 2025. PAs should only claim credit commensurate with the extent of their participation.